Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Mesalazin (ausschl. Dafo TMR), ATC A07EC02 für die Zeit 01.06.2026 - 31.05.2028 (zzgl. V.-Option 1x12 Mon)

Section 130a, paragraph 8, SGB V allows health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. With regard to the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Annex 2 to the contract, for the aforementioned active substance Mesalazin (exclusively in the dosage form TMR, excluding the strength 500 mg), ATC A07EC02, DAK-Gesundheit intends to conclude discount contracts for medicines with as many interested pharmaceutical companies as possible until the entry into force of new pharmaceutical discount contracts. A discount contract under the approval model for the aforementioned active substance will come into force for the first time on 01.06.2026 and will end on 31.05.2028 (plus extension option 1x12 months). It will end automatically with the entry into force of the exclusive contract, regardless.